论文部分内容阅读
目的分析甘精胰岛素联合瑞格列奈治疗初发2型糖尿病的临床效果和安全性。方法采用随机数字表法将97例初发2型糖尿病确诊患者分为两组,对照组49例予诺和灵30R治疗,实验组48例予甘精胰岛素联合瑞格列奈治疗,观察治疗前后血糖指标变化、血糖达标时间、胰岛素用量和低血糖发生情况。结果两组治疗后与治疗前比较,均能够降低血糖指标,差异有统计学意义(P<0.01);两组治疗后组间比较,差异无统计学意义(P>0.05);观察组治疗后与对照组比较,血糖达标时间短,胰岛素使用量少,低血糖发生率低,差异有统计学意义(P<0.05)。结论甘精胰岛素联合瑞格列奈治疗初发2型糖尿病疗效确切,能够有效控制血糖指标,缩短血糖达标时间,降低胰岛素使用量和低血糖发生率,在改善患者生存质量和预防糖尿病并发症方面具有重要的意义。
Objective To analyze the clinical efficacy and safety of insulin glargine plus repaglinide in the treatment of newly diagnosed type 2 diabetes mellitus. Methods Ninety-seven patients with newly diagnosed type 2 diabetes mellitus were divided into two groups by random number table method, 49 patients in control group received Novolin 30R, and 48 in experimental group were treated with insulin glargine and repaglinide. Before and after treatment Changes in blood glucose, blood glucose compliance time, the amount of insulin and hypoglycemia. Results After treatment, both groups were able to lower the blood glucose level after treatment compared with before treatment, the difference was statistically significant (P <0.01). There was no significant difference between the two groups after treatment (P> 0.05) Compared with the control group, blood glucose reached a short time, less insulin, low incidence of hypoglycemia, the difference was statistically significant (P <0.05). Conclusion Glargine and repaglinide are effective in treating newly diagnosed type 2 diabetes mellitus, which can effectively control the blood sugar level, shorten the time of reaching the target of blood glucose, reduce the dosage of insulin and incidence of hypoglycemia, and improve the quality of life and prevent the complication of diabetes It is of great significance.